Professional Diagnostics
Diagenics Group SE is a biopharmaceutical enterprise with branch offices and partners in Europe and the USA. We are developers and producers of a new line of diagnostic products based on a new and innovative bio-marker. The potential of our products will change and improve the medical diagnosis.
Reimbursement by
Early detection in emergencies such as stroke, heart attack and pre-eclampsia is one of the most important factors and thus decisively determines the life and death of the person concerned. With the development of our innovative diagnostic products, we have succeeded in finding more specific and effective solutions for the early detection of such essential health disorders.
Rapid Antigen Tests*
Our rapid antigen tests are already registered on the BfArM list according to the Paul Ehrlich Institute / Robert Koch Institute and WHO criteria for Covid-19 antigen tests.
Diagenics Group SE is a biopharmaceutical company and is a pioneer in innovative diagnostics for the early detection of important diseases such as heart attack (ACS), stroke and preeclampsia. This early detection is based on a new and innovative biomarker that was developed by Diagenics Group SE. Diagnostic results are faster and more accurate, which in turn is inexpensive and reduces the frequency of misdiagnosis.
Product Lines
DIANEONATAL®
DIACORDON®
DIASTROKE®
DIA-COVID®
DIANEONATAL®
DIACORDON®
DIASTROKE®
Clinical Partners
